Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice

Molecular Pharmaceutics

Volumn 6, Issue 2, 2009, Pages 428-440

  Zou, Peng ^a   Xu, Songbo ^a   Povoski, Stephen P ^b   Wang, Anna ^a   Johnson, Morgan A ^b   Martin Jr , Edward W ^b   Subramaniam, Vish ^c   Xu, Ronald ^a   Sun, Duxin ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

CC49; Cy7; Fluorescence; TAG 72; Tumor imaging

Indexed keywords

FLUORESCENT DYE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY TAG 72; N HYDROXYSUCCINIMIDE; TAG 72 ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER LOCALIZATION; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SYNTHESIS; FEMALE; FLUORESCENCE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MOUSE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; COLORECTAL NEOPLASMS; DIAGNOSTIC IMAGING; FEMALE; FLUORESCENT DYES; GLYCOPROTEINS; HUMANS; MICE; MICE, NUDE; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 64649093415     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp9000052     Document Type: Article

References (53)

1. Johnson, V. G.; Schlom, J.; Paterson, A. J.; Bennett, J.; Magnani, J. L.; Colcher, D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res. 1986, 46 (2), 850-857.
2. Colcher, D.; Milenic, D.; Roselli, M.; Raubitschek, A.; Yarranton, G.; King, D.; Adair, J.; Whittle, N.; Bodmer, M.; Schlom, J. Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res. 1989, 49 (7), 1738-1745.
3. Xiao, J.; Horst, S.; Hinkle, G.; Cao, X.; Kocak, E.; Fang, J.; Young, D.; Khazaeli, M.; Agnese, D.; Sun, D.; Martin, E. W., Jr. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients. Cancer Biother. Radiopharm. 2005, 20 (1), 16-26.
4. Fang, L.; Holford, N. H. G.; Hinkle, G.; Cao, X.; Bloomston, M.; Xiao, J.; Gibbs, S.; Al Saif, O. H.; Dalton, J. T.; Chan, K. K.; Schlom, J., Jr.; Sun, D. Population Pharmacokinetics of Humanized Monoclonal Antibody HuCC49δCH2 and Murine Antibody CC49 in Colorectal Cancer Patients. J. Clin. Pharmacol. 2007, 47, 227-237.
5. Nieroda, C. A.; Mojzisik, C.; Hinkle, G.; Thurston, M. O.; Martin, E. W., Jr. Radioimmunoguided surgery (RIGS) in recurrent colorectal cancer. Cancer Detect. Prev. 1991, 15 (3), 225-229.
6. Nieroda, C. A.; Mojzisik, C.; Sardi, A.; Ferrara, P.; Hinkle, G.; Thurston, M. O.; Martin, E. W., Jr. The impact of radioimmu- noguided surgery (RIGS) on surgical decision-making in colorectal cancer. Dis. Colon Rectum 1989, 32 (11), 927-932.
7. Sardi, A.; Workman, M.; Mojzisik, C.; Hinkle, G.; Nieroda, C.; Martin, E. W., Jr. Intra-abdominal recurrence of colorectal cancer detected by radioimmunoguided surgery (RIGS system). Arch. Surg. 1989, 124 (1), 55-59.
8. Bertsch, D. J.; Burak, W. E., Jr.; Young, D. C.; Arnold, M. W.; Martin, E. W., Jr. Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer. Surgery 1995, 118 (4), 634-638.
9. Bertsch, D. J.; Burak, W. E., Jr.; Young, D. C.; Arnold, M. W.; Martin, E. W., Jr. Radioimmunoguided surgery for colorectal cancer. Ann Surg Oncol 1996, 3 (3), 310-316.
10. Gardner, B. Five-year survival after extended resection of colon cancer. J. Surg. Oncol. 1987, 34 (4), 258-261.
11. Arnold, M. W.; Young, D. C.; Hitchcock, C. L.; Schneebaum, S.; Martin, E. W., Jr. Radioimmunoguided surgery in primary colorectal carcinoma: an intraoperative prognostic tool and adjuvant to traditional staging. Am. J. Surg 1995, 170 (4), 315-318.
12. Molinolo, A.; Simpson, J. F.; Thor, A.; Schlom, J. Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res. 1990, 50 (4), 1291-1298.
13. Sickle-Santanello, B. J.; O'Dwyer, P. J.; Mojzisik, C.; Tuttle, S. E.; Hinkle, G. H.; Rousseau, M.; Schlom, J.; Colcher, D.; Thurston, M. O.; Nieroda, C. Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors. Dis. Colon Rectum 1987, 30 (10), 761-764.
14. Nieroda, C. A.; Mojzisik, C.; Sardi, A.; Ferrara, P. J.; Hinkle, G.; Thurston, M. O.; Martin, E. W., Jr. Radioimmunoguided surgery in primary colon cancer. Cancer Detect. Prev. 1990, 14 (6), 651-656.
15. Cohen, A. M.; Martin, E. W., Jr.; Lavery, I.; Daly, J.; Sardi, A.; Aitken, D.; Bland, K.; Mojzisik, C.; Hinkle, G. Radioimmunogu- ided surgery using iodine 125 B72.3 in patients with colorectal cancer. Arch. Surg. 1991, 126 (3), 349-352.
16. Martin, E. W., Jr.; Thurston, M. O. Intraoperative radioimmuno- detection. Semin. Surg. Oncol. 1998, 15 (4), 205-208.
17. Agnese, D. M.; Abdessalam, S. F.; Burak, W. E., Jr.; Arnold, M. W.; Soble, D.; Hinkle, G. H.; Young, D.; Khazaeli, M. B.; Martin, E. W., Jr. Pilot study using a humanized CC49 monoclonal antibody (HuCC49DeltaCH2) to localize recurrent colorectal carcinoma. Ann. Surg. Oncol 2004, 11 (2), 197-202.
18. Martinez, D. A.; Barbera-Guillem, E.; LaValle, G. J.; Martin, E. W., Jr. Radioimmunoguided Surgery for Gastrointestinal Malignancies: An Analysis of 14 Years of Clinical Experience. Cancer Control 1997, 4 (6), 505-516.
19. LaValle, G. J.; Martinez, D. A.; Sobel, D.; DeYoung, B.; Martin, E. W., Jr. Assessment of disseminated pancreatic cancer: a comparison of traditional exploratory laparotomy and radioim- munoguided surgery. Surgery 1997, 122 (5), 867-871.
20. Arnold, M. W.; Young, D. M.; Hitchcock, C. L.; Barbera-Guillem, E.; Nieroda, C.; Martin, E. W., Jr. Staging of colorectal cancer: biology vs. morphology. Dis. Colon Rectum 1998, 41 (12), 1482-1487.
21. Arnold, M. W.; Schneebaum, S.; Berens, A.; Petty, L.; Mojzisik, C.; Hinkle, G.; Martin, E. W., Jr. Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second-generation monoclonal antibody. Ann. Surg. 1992, 216 (6), 627-632.
22. Arnold, M. W.; Hitchcock, C. L.; Young, D. C.; Burak, W. E., Jr.; Bertsch, D. J.; Martin, E. W., Jr. Intra-abdominal patterns of disease dissemination in colorectal cancer identified using radio- immunoguided surgery. Dis. Colon Rectum 1996, 39 (5), 509-513.
23. Arnold, M. W.; Schneebaum, S.; Martin, E. W., Jr. Cancer Control 1996, 3 (1), 42-45.
24. Cote, R. J.; Houchens, D. P.; Hitchcock, C. L.; Saad, A. D.; Nines, R. G.; Greenson, J. K.; Schneebaum, S.; Arnold, M. W.; Martin, E. W., Jr. Cancer 1996, 77 (4), 613-620.
25. Sardi, A.; Agnone, C. M.; Nieroda, C. A.; Mojzisik, C.; Hinkle, G.; Ferrara, P.; Farrar, W. B.; Bolton, J.; Thurston, M. O.; Martin, E. W., Jr. Radioimmunoguided surgery in recurrent colorectal cancer: the role of carcinoembryonic antigen, computerized tomography, and physical examination. South Med. J. 1989, 82 (10), 1235-1244.
26. Kim, J. A.; Triozzi, P. L.; Martin, E. W., Jr. Radioimmunoguided surgery for colorectal cancer. Oncology (Williston Park) 1993, 7 (2), 55-60.
27. Arnold, M. W.; Schneebaum, S.; Berens, A.; Mojzisik, C.; Hinkle, G.; Martin, E. W., Jr. Radioimmunoguided surgery challenges traditional decision making in patients with primary colorectal cancer. Surgery 1992, 112 (4), 624-629.
28. Schneebaum, S.; Arnold, M. W.; Houchens, D. P.; Greenson, J. K.; Cote, R. J.; Hitchcock, C. L.; Young, D. C.; Mojzisik, C. M.; Martin, E. W., Jr. The significance of intraoperative periportal lymph node metastasis identification in patients with colorectal carcinoma. Cancer 1995, 75 (12), 2809-2817.
29. Sun, D.; Bloomston, M.; Hinkle, G.; Al-Saif, O. H.; Hall, N. C.; Povoski, S. P.; Arnold, M. W.; Martin, E. W., Jr. Radioimmu- noguided surgery (RIGS), PET/CT image-guided surgery, and fluorescence image-guided surgery: Past, present, and future. J. Surg. Oncol. 2007, 96 (4), 297-308.
30. King, M. A.; Pretorius, P. H.; Farncombe, T.; Beekman, F. J. Introduction to the physics of molecular imaging with radioactive tracers in small animals. J. Cell. Biochem. 2002, 39, 221-230.
31. Ke, S.; Wen, X.; Gurfinkel, M.; Charnsangavej, C.; Wallace, S.; Sevick-Muraca, E. M.; Li, C. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res. 2003, 63 (22), 7870-7875.
32. Cheng, Z.; Levi, J.; Xiong, Z.; Gheysens, O.; Keren, S.; Chen, X.; Gambhir, S. S. Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. Bioconjugate Chem. 2006, 17 (3), 662-669.
33. Cheng, Z.; Wu, Y.; Xiong, Z.; Gambhir, S. S.; Chen, X. Near- infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjugate Chem. 2005, 16 (6), 1433-1441.
34. Tanisaka, H.; Kizaka-Kondoh, S.; Makino, A.; Tanaka, S.; Hiraoka, M.; Kimura, S. Near-infrared fluorescent labeled pep- tosome for application to cancer imaging. Bioconjugate Chem. 2008, 19 (1), 109-117.
35. Hawrysz, D. J.; Sevick-Muraca, E. M. Developments toward diagnostic breast cancer imaging using near-infrared optical measurements and fluorescent contrast agents. Neoplasia 2000, 2 (5), 388-417.
36. Nimura, H.; Narimiya, N.; Mitsumori, N.; Yamazaki, Y.; Yanaga, K.; Urashima, M. Infrared ray electronic endoscopy combined with indocyanine green injection for detection of sentinel nodes of patients with gastric cancer. Br. J. Surg. 2004, 91 (5), 575-579.
37. Soltesz, E. G.; Kim, S.; Kim, S. W.; Laurence, R. G.; De Grand, A. M.; Parungo, C. P.; Cohn, L. H.; Bawendi, M. G.; Frangioni, J. V. Sentinel lymph node mapping of the gastrointestinal tract by using invisible light. Ann. Surg. Oncol. 2006, 13 (3), 386-396.
38. Gleysteen, J. P.; Newman, J. R.; Chhieng, D.; Frost, A.; Zinn, K. R.; Rosenthal, E. L. Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head Neck 2008, 30 (6), 782-789.
39. Rosenthal, E. L.; Kulbersh, B. D.; King, T.; Chaudhuri, T. R.; Zinn, K. R. Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts. Mol. Cancer Ther. 2007, 6 (4), 1230-1238.
40. Kulbersh, B. D.; Duncan, R. D.; Magnuson, J. S.; Skipper, J. B.; Zinn, K.; Rosenthal, E. L. Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts. Arch. Otolaryngol. 2007, 133 (5), 511-515.
41. Rosenthal, E. L.; Kulbersh, B. D.; Duncan, R. D.; Zhang, W. Y.; Magnuson, J. S.; Carroll, W. R.; Zinn, K. In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence. Larynsoscope 2006,116 (9), 1636-1641.
42. Healthcare, G. Protocol for Amersham CyDye monoreactive NHS Esters. 2006.
43. Fang, L.; Battisti, R. F.; Cheng, H.; Reigan, P.; Xin, Y.; Shen, J.; Ross, D.; Chan, K. K.; Martin, E. W., Jr.; Wang, P. G.; Sun, D. Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta- galactosidase conjugates. J. Med. Chem 2006, 49 (21), 6290-6297.
44. Xu, R. X.; Povoski, S. P. Diffuse optical imaging and spectroscopy for cancer. Expert Rev. Med. Devices 2007, 4 (1), 83-95.
45. Gruber, H. J.; Hahn, C. D.; Kada, G.; Riener, C. K.; Harms, G. S.; Ahrer, W.; Dax, T. G.; Knaus, H. G. Anomalous fluorescence enhancement of Cy3 and Cy3.5 versus anomalous fluorescence loss of Cy5 and Cy7 upon covalent linking to IgG and noncovalent binding to avidin. Bioconiugate Chem. 2000, 11 (5), 696-704.
46. Mujumdar, R. B.; Ernst, L. A.; Mujumdar, S. R.; Lewis, C. J.; Waggoner, A. S. Cyanine dye labeling reagents: sulfoindocyanine succinimidyl esters. Bioconiugate Chem. 1993, 4 (2), 105-111.
47. Slavin-Chiorini, D. C.; Kashmiri, S. V.; Schlom, J.; Calvo, B.; Shu, L. M.; Schott, M. E.; Milenic, D. E.; Snoy, P.; Carrasquillo, J.; Anderson, K. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res. 1995, 55 (23), 5957s-5967s.
48. Milenic, D. E.; Garmestani, K.; Chappell, L. L.; Dadachova, E.; Yordanov, A.; Ma, D. S.; Schlom, J.; Brechbiel, M. W. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with Lu-177 for radioimmunotherapeutic applications. Nucl. Med. Biol. 2002, 29 (4), 431-442.
49. Rogers, B. E.; Roberson, P. L.; Shen, S.; Khazaeli, M. B.; Carpenter, M.; Yokoyama, S.; Brechbiel, M. W.; LoBuglio, A. F.; Buchsbaum, D. J. Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region. Cancer Biother. Radiopharm. 2005, 20 (5), 502-513.
50. Mohsin, H.; Jia, F.; Sivaguru, G.; Hudson, M. J.; Shelton, T. D.; Hoffman, T. J.; Cutler, C. S.; Ketring, A. R.; Athey, P. S.; Simon, J.; Frank, R. K.; Jurisson, S. S.; Lewis, M. R. Radiolanthanide- labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: Biological comparison of DOTA conjugates and Pm-149, Ho-166, and Lu-177. Bioconjugate Chem. 2006, 17 (2), 485-492.
51. Yokota, T.; Milenic, D. E.; Whitlow, M.; Wood, J. F.; Hubert, S. L.; Schlom, J. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res. 1993, 53 (16), 3776-3783.
52. Sampath, L.; Kwon, S.; Ke, S.; Wang, W.; Schiff, R.; Mawad, M. E.; Sevick-Muraca, E. M. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J. Nucl. Med. 2007, 48 (9), 1501-1510.
53. Chinn, P. C.; Morena, R. A.; Santoro, D. A.; Kazules, T.; Kashmiri, S. V. S.; Schlom, J.; Hanna, N.; Braslawsky, G. Pharmacokinetics and ibmor localization of In-111-labeled HuCC49 Delta C(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft. Cancer Biother. Radiopharm. 2006, 21 (2), 106-116.